ArticleActa paediatrica (Oslo, Norway : 1992)2026
In Vitro Performance of Valved Holding Chambers in Paediatric Asthma Controller Therapy.
Article in Acta paediatrica (Oslo, Norway : 1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
aimResearch on the drug delivery of inhaled corticosteroids and combination medications via valved holding chambers (VHCs) with children's breathing patterns is limited. We aimed to evaluate the in vitro performance of commercially available VHCs without facemasks under preschooler breathing conditions, focusing on total delivered dose and fine particle dose (FPD).
methodsWe evaluated the FPD in 1-5 μm range of fluticasone/salmeterol combination inhaler, fluticasone propionate mono-inhaler, and ciclesonide delivered through three VHCs: AeroChamber Plus Flow-Vu, EasyChamber, and OptiChamber Diamond. Drug delivery was measured using a Next Generation Impactor with simulated breathing representative of a 4-year-old child.
resultsThe total delivered dose compared to the label claim was highest for ciclesonide with all the VHCs. The median FPD in 1-5 μm range was significantly higher with EasyChamber compared to AeroChamber and OptiChamber for salmeterol and fluticasone from combination-inhaler and ciclesonide. Overall, relative throat deposition was lowest for ciclesonide and highest for fluticasone mono-inhaler. OptiChamber yielded lowest relative throat depositions for ciclesonide and fluticasone mono-inhaler, while EasyChamber gave lowest relative throat depositions for salmeterol and fluticasone from combination inhaler.
conclusionThere were notable differences between the tested VHC's drug delivery. Ciclesonide exhibited favourable aerodynamic properties than fluticasone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.